Patient treatment history for anti-CTLA-4 and anti-PD-1 treated patients

Anti-CTLA-4 patients treatment history
	Total patients	Treatment naïve	Treatment experienced	Checkpoint blockade experienced
Responders	10	10	0	0
Non-responders	14	8	6	0
Total patients	24	18	6	0
Anti-CTLA-4 patients treatment experienced
	Treatment experienced		Ave. months between end of prior treatment and anti-CTLA-4 therapy	Range (months)
Responders	0		N/A	N/A
Non-responders	6		2.5	< 1~ 11
Anti-PD-1 patients treatment history
	Total patients	Treatment naive	Treatment experienced	Checkpoint blockade experienced	Nivolumab experienced
Responders	21	8	13	12	1
Non-responders	19	6	13	11	2
Total patients	40	14	26	23	3
Anti-PD-1 patients treatment experienced
	Treatment experienced	Ave. months between end of prior treatment and anti-PD-1 therapy		STDEV (months)	U test p value between groups
Responders	13	6.3		7.1	0.59
Non-responders	13	4.5		6.6	0.59

The above tables list the number of patients who were treatment naïve and treatment experienced in either the anti-CTLA-4 or anti-PD-1 cohort. In the anti-CTLA-4 cohort, 6 out of 24 patients were treatment experienced. None of them had experienced prior checkpoint blockade therapies. The average and range of time window (months) from end of prior therapy of any kind and start of anti-CTLA-4 are shown. Among anti-PD-1 patients, the majority of treatment experienced patients had prior checkpoint blockade therapies (23/26). Of these, 3 had prior nivolumab (in combination or sequential therapies with ipilimumab and other modalities). The average time window (months) from end of prior therapy of any kind and start of anti-PD-1 in both responders and non-responders are shown. Standard deviation of the time window in responders and non-responders are listed. Mann-Whitney U test was used to compare responders and non-responders